Limiting hESC patents in China under a dual-value perspective: Chinese patent law has several tools available to avoid patent thickets and patent monopolization: Chinese patent law has several tools available to avoid patent thickets and patent monopolization.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Development of mesenchymal stem cells: therapeutic effect and prospect for rheumatoid arthritis.Stem cell research & therapy · 2025
   Review
2. How to promote the accessibility of technology in the era of hESC patents-A comparative analysis of the systems of the US and China.Stem cell reports · 2023
   Review
3. Limiting hESC patents in China under a dual-value perspective: Chinese patent law has several tools available to avoid patent thickets and patent monopolization: Chinese patent law has several tools available to avoid patent thickets and patent monopolization.EMBO reports · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as